<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p163" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_163{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_163{left:306px;bottom:30px;}
#t3_163{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_163{left:346px;bottom:30px;}
#t5_163{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_163{left:517px;bottom:30px;}
#t7_163{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_163{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_163{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_163{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_163{left:35px;bottom:777px;letter-spacing:0.1px;word-spacing:0.09px;}
#tc_163{left:35px;bottom:754px;letter-spacing:0.1px;word-spacing:0.08px;}
#td_163{left:35px;bottom:731px;letter-spacing:0.13px;word-spacing:0.06px;}
#te_163{left:262px;bottom:738px;letter-spacing:-0.01px;}
#tf_163{left:285px;bottom:731px;letter-spacing:0.21px;word-spacing:-0.02px;}
#tg_163{left:35px;bottom:707px;letter-spacing:0.04px;word-spacing:0.15px;}
#th_163{left:35px;bottom:667px;letter-spacing:0.23px;word-spacing:-0.04px;}
#ti_163{left:35px;bottom:645px;letter-spacing:0.11px;word-spacing:-0.33px;}
#tj_163{left:35px;bottom:622px;letter-spacing:0.12px;word-spacing:0.06px;}
#tk_163{left:35px;bottom:599px;letter-spacing:0.07px;word-spacing:0.11px;}
#tl_163{left:35px;bottom:575px;letter-spacing:0.06px;word-spacing:0.13px;}
#tm_163{left:35px;bottom:552px;letter-spacing:-0.08px;word-spacing:0.27px;}
#tn_163{left:181px;bottom:560px;letter-spacing:0.1px;}
#to_163{left:226px;bottom:552px;letter-spacing:0.07px;word-spacing:0.12px;}
#tp_163{left:35px;bottom:529px;letter-spacing:0.12px;word-spacing:-0.7px;}
#tq_163{left:35px;bottom:506px;letter-spacing:0.05px;word-spacing:-0.88px;}
#tr_163{left:35px;bottom:482px;letter-spacing:0.25px;word-spacing:-0.06px;}
#ts_163{left:374px;bottom:490px;letter-spacing:-0.01px;}
#tt_163{left:397px;bottom:482px;letter-spacing:0.14px;word-spacing:0.04px;}
#tu_163{left:35px;bottom:459px;letter-spacing:0.13px;word-spacing:0.06px;}
#tv_163{left:35px;bottom:436px;letter-spacing:0.13px;word-spacing:0.06px;}
#tw_163{left:35px;bottom:413px;letter-spacing:0.04px;word-spacing:0.15px;}
#tx_163{left:35px;bottom:390px;letter-spacing:0.14px;word-spacing:0.05px;}
#ty_163{left:35px;bottom:366px;letter-spacing:0.06px;word-spacing:0.12px;}
#tz_163{left:35px;bottom:343px;letter-spacing:0.06px;word-spacing:-1.1px;}
#t10_163{left:35px;bottom:320px;letter-spacing:0.19px;}
#t11_163{left:35px;bottom:297px;letter-spacing:0.14px;word-spacing:0.05px;}
#t12_163{left:35px;bottom:273px;letter-spacing:0.15px;word-spacing:-1.19px;}
#t13_163{left:389px;bottom:281px;}
#t14_163{left:434px;bottom:273px;letter-spacing:-0.02px;word-spacing:0.21px;}
#t15_163{left:35px;bottom:250px;letter-spacing:0.08px;word-spacing:0.1px;}
#t16_163{left:35px;bottom:227px;letter-spacing:0.13px;word-spacing:0.06px;}
#t17_163{left:35px;bottom:204px;letter-spacing:0.08px;word-spacing:0.11px;}
#t18_163{left:246px;bottom:211px;letter-spacing:0.1px;}
#t19_163{left:291px;bottom:204px;word-spacing:0.18px;}
#t1a_163{left:35px;bottom:181px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1b_163{left:318px;bottom:181px;}
#t1c_163{left:335px;bottom:181px;letter-spacing:0.17px;word-spacing:0.02px;}
#t1d_163{left:35px;bottom:157px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1e_163{left:35px;bottom:134px;letter-spacing:0.16px;word-spacing:0.03px;}
#t1f_163{left:563px;bottom:134px;}
#t1g_163{left:579px;bottom:134px;}
#t1h_163{left:35px;bottom:111px;letter-spacing:0.12px;word-spacing:-1.17px;}
#t1i_163{left:35px;bottom:88px;}
#t1j_163{left:51px;bottom:88px;letter-spacing:0.18px;word-spacing:0.01px;}
#t1k_163{left:505px;bottom:88px;}
#t1l_163{left:521px;bottom:88px;letter-spacing:0.23px;word-spacing:-0.05px;}
#t1m_163{left:35px;bottom:64px;letter-spacing:0.14px;word-spacing:0.04px;}
#t1n_163{left:414px;bottom:64px;}
#t1o_163{left:430px;bottom:64px;letter-spacing:0.23px;word-spacing:-0.05px;}
#t1p_163{left:490px;bottom:72px;letter-spacing:-0.01px;}
#t1q_163{left:618px;bottom:777px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1r_163{left:618px;bottom:754px;letter-spacing:0.06px;word-spacing:0.12px;}
#t1s_163{left:618px;bottom:731px;letter-spacing:0.06px;}
#t1t_163{left:680px;bottom:738px;}
#t1u_163{left:724px;bottom:731px;letter-spacing:0.06px;word-spacing:-0.73px;}
#t1v_163{left:618px;bottom:707px;letter-spacing:0.09px;word-spacing:-0.86px;}
#t1w_163{left:618px;bottom:684px;letter-spacing:0.14px;word-spacing:0.05px;}
#t1x_163{left:1034px;bottom:692px;letter-spacing:0.1px;}
#t1y_163{left:1079px;bottom:684px;letter-spacing:0.08px;word-spacing:0.1px;}
#t1z_163{left:618px;bottom:661px;letter-spacing:0.03px;word-spacing:0.16px;}
#t20_163{left:618px;bottom:638px;letter-spacing:0.19px;}
#t21_163{left:618px;bottom:614px;letter-spacing:0.11px;word-spacing:0.08px;}
#t22_163{left:618px;bottom:591px;letter-spacing:0.19px;}
#t23_163{left:618px;bottom:568px;letter-spacing:0.08px;}
#t24_163{left:732px;bottom:576px;letter-spacing:-0.01px;}
#t25_163{left:754px;bottom:568px;letter-spacing:0.1px;word-spacing:-0.38px;}
#t26_163{left:618px;bottom:545px;letter-spacing:-0.14px;}
#t27_163{left:702px;bottom:552px;letter-spacing:-0.01px;}
#t28_163{left:618px;bottom:506px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t29_163{left:618px;bottom:482px;letter-spacing:0.1px;word-spacing:0.09px;}
#t2a_163{left:618px;bottom:459px;letter-spacing:0.06px;word-spacing:0.13px;}
#t2b_163{left:618px;bottom:436px;letter-spacing:0.11px;word-spacing:0.07px;}
#t2c_163{left:618px;bottom:413px;letter-spacing:0.1px;word-spacing:0.09px;}
#t2d_163{left:618px;bottom:390px;letter-spacing:-0.13px;word-spacing:0.33px;}
#t2e_163{left:689px;bottom:390px;}
#t2f_163{left:705px;bottom:390px;letter-spacing:0.23px;word-spacing:-0.04px;}
#t2g_163{left:750px;bottom:397px;letter-spacing:-0.01px;}
#t2h_163{left:772px;bottom:390px;letter-spacing:0.05px;word-spacing:-1.1px;}
#t2i_163{left:618px;bottom:366px;letter-spacing:0.09px;word-spacing:0.1px;}
#t2j_163{left:618px;bottom:343px;letter-spacing:0.15px;word-spacing:0.04px;}
#t2k_163{left:618px;bottom:320px;letter-spacing:0.09px;word-spacing:0.1px;}
#t2l_163{left:875px;bottom:327px;letter-spacing:0.1px;}
#t2m_163{left:920px;bottom:320px;letter-spacing:0.11px;word-spacing:0.07px;}
#t2n_163{left:618px;bottom:297px;letter-spacing:0.12px;word-spacing:0.06px;}
#t2o_163{left:618px;bottom:273px;letter-spacing:0.14px;word-spacing:-0.94px;}
#t2p_163{left:1155px;bottom:281px;letter-spacing:-0.01px;}
#t2q_163{left:618px;bottom:250px;letter-spacing:0.12px;word-spacing:0.06px;}
#t2r_163{left:618px;bottom:227px;letter-spacing:0.12px;word-spacing:0.07px;}
#t2s_163{left:618px;bottom:204px;letter-spacing:0.14px;word-spacing:0.05px;}
#t2t_163{left:741px;bottom:211px;letter-spacing:-0.01px;}
#t2u_163{left:618px;bottom:163px;letter-spacing:0.15px;word-spacing:0.04px;}
#t2v_163{left:618px;bottom:140px;letter-spacing:0.12px;word-spacing:0.06px;}
#t2w_163{left:618px;bottom:117px;letter-spacing:0.08px;}
#t2x_163{left:732px;bottom:125px;letter-spacing:-0.01px;}
#t2y_163{left:755px;bottom:117px;word-spacing:0.19px;}
#t2z_163{left:618px;bottom:94px;letter-spacing:0.09px;word-spacing:0.1px;}
#t30_163{left:871px;bottom:101px;letter-spacing:-0.01px;}
#t31_163{left:895px;bottom:94px;letter-spacing:0.13px;word-spacing:0.05px;}
#t32_163{left:618px;bottom:71px;letter-spacing:0.13px;word-spacing:-1.04px;}
#t33_163{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_163{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_163{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_163{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_163{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_163{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_163{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s6_163{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s7_163{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts163" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg163Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg163" style="-webkit-user-select: none;"><object width="1210" height="935" data="163/163.svg" type="image/svg+xml" id="pdf163" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_163" class="t s0_163">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_163" class="t s1_163">© </span>
<span id="t3_163" class="t s0_163">(NCCN </span>
<span id="t4_163" class="t s1_163">© </span>
<span id="t5_163" class="t s0_163">), All rights reserved. NCCN Guidelines </span>
<span id="t6_163" class="t s1_163">® </span>
<span id="t7_163" class="t s0_163">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_163" class="t s2_163">NCCN Guidelines Version 4.2024 </span>
<span id="t9_163" class="t s2_163">Head and Neck Cancers </span>
<span id="ta_163" class="t s3_163">MS-22 </span>
<span id="tb_163" class="t s4_163">91-11 trial confirmed that concomitant systemic therapy/RT improved the </span>
<span id="tc_163" class="t s4_163">larynx preservation rate and that induction chemotherapy followed by RT </span>
<span id="td_163" class="t s4_163">was not superior to RT alone. </span>
<span id="te_163" class="t s5_163">288 </span>
<span id="tf_163" class="t s4_163">However, OS did not differ among the </span>
<span id="tg_163" class="t s4_163">three treatment arms. </span>
<span id="th_163" class="t s4_163">Nonetheless, interest in the role of induction chemotherapy endures for </span>
<span id="ti_163" class="t s4_163">several reasons. First, advances in surgery, RT, and concurrent systemic </span>
<span id="tj_163" class="t s4_163">therapy/RT have yielded improvements in locoregional control; thus, the </span>
<span id="tk_163" class="t s4_163">role of distant metastases as a source of treatment failure has increased, </span>
<span id="tl_163" class="t s4_163">and induction chemotherapy is a strategy that may reduce the risk of </span>
<span id="tm_163" class="t s4_163">distant metastases. </span>
<span id="tn_163" class="t s5_163">295,296 </span>
<span id="to_163" class="t s4_163">Second, clinicians have increasing concern </span>
<span id="tp_163" class="t s4_163">regarding the long-term morbidity of concurrent systemic therapy/RT, and </span>
<span id="tq_163" class="t s4_163">thus have an interest in exploring alternative approaches that might have a </span>
<span id="tr_163" class="t s4_163">more favorable long-term side effect profile. </span>
<span id="ts_163" class="t s5_163">297 </span>
<span id="tt_163" class="t s4_163">Finally, a more effective </span>
<span id="tu_163" class="t s4_163">triplet induction chemotherapy regimen was identified compared to the </span>
<span id="tv_163" class="t s4_163">standard cisplatin/5-FU used in the induction trials of the 1980s and </span>
<span id="tw_163" class="t s4_163">1990s, and analyzed in the related meta-analyses. Three phase III trials </span>
<span id="tx_163" class="t s4_163">compared induction cisplatin plus 5-FU with or without the addition of a </span>
<span id="ty_163" class="t s4_163">taxane (docetaxel or paclitaxel) followed by the same locoregional </span>
<span id="tz_163" class="t s4_163">treatment in both groups. Results showed significantly improved outcomes </span>
<span id="t10_163" class="t s4_163">(response rates, DFS, or OS, depending on the trial) for patients in the </span>
<span id="t11_163" class="t s4_163">three-drug induction group (taxane plus cisplatin and 5-FU) compared to </span>
<span id="t12_163" class="t s4_163">those receiving two drugs (cisplatin plus 5-FU). </span>
<span id="t13_163" class="t s5_163">298-301 </span>
<span id="t14_163" class="t s4_163">A randomized phase </span>
<span id="t15_163" class="t s4_163">III trial in the larynx preservation setting similarly showed superior larynx </span>
<span id="t16_163" class="t s4_163">preservation outcome with induction docetaxel/cisplatin/5-FU (TPF) </span>
<span id="t17_163" class="t s4_163">compared to cisplatin/5-FU. </span>
<span id="t18_163" class="t s5_163">302,303 </span>
<span id="t19_163" class="t s4_163">A meta-analysis including five </span>
<span id="t1a_163" class="t s4_163">randomized controlled trials (RCTs) (</span><span id="t1b_163" class="t s6_163">N </span><span id="t1c_163" class="t s4_163">= 1772) showed that the TPF </span>
<span id="t1d_163" class="t s4_163">induction chemotherapy regimen, compared to cisplatin plus 5-FU, was </span>
<span id="t1e_163" class="t s4_163">associated with reduced risk of death (HR, 0.72; 95% CI, 0.63–0.83; </span><span id="t1f_163" class="t s6_163">P </span><span id="t1g_163" class="t s4_163">&lt; </span>
<span id="t1h_163" class="t s4_163">.001) and greater reductions in progression (HR, 0.78; 95% CI, 0.69–0.87; </span>
<span id="t1i_163" class="t s6_163">P </span><span id="t1j_163" class="t s4_163">&lt; .001), locoregional failure (HR, 0.79; 95% CI, 0.66–0.94; </span><span id="t1k_163" class="t s6_163">P </span><span id="t1l_163" class="t s4_163">= .007), </span>
<span id="t1m_163" class="t s4_163">and distant failure (HR, 0.63; 95% CI, 0.45–0.89; </span><span id="t1n_163" class="t s6_163">P </span><span id="t1o_163" class="t s4_163">= .009). </span>
<span id="t1p_163" class="t s5_163">304 </span>
<span id="t1q_163" class="t s4_163">Whether adding induction chemotherapy to concurrent chemoradiation </span>
<span id="t1r_163" class="t s4_163">(versus RT alone) results in a clear advantage in OS continues is </span>
<span id="t1s_163" class="t s4_163">unclear. </span>
<span id="t1t_163" class="t s5_163">305-307 </span>
<span id="t1u_163" class="t s4_163">Both the DeCIDE and the PARADIGM phase III trials did not </span>
<span id="t1v_163" class="t s4_163">convincingly show a survival advantage with the incorporation of induction </span>
<span id="t1w_163" class="t s4_163">chemotherapy followed by concurrent chemoradiation. </span>
<span id="t1x_163" class="t s5_163">306,307 </span>
<span id="t1y_163" class="t s4_163">In patients </span>
<span id="t1z_163" class="t s4_163">with stage III or IV SCCHN, a randomized phase II study compared </span>
<span id="t20_163" class="t s4_163">induction TPF followed by concurrent cisplatin/5-FU and RT versus </span>
<span id="t21_163" class="t s4_163">concurrent cisplatin/5-FU and RT alone. A higher radiologic complete </span>
<span id="t22_163" class="t s4_163">response rate was reported with the incorporation of induction </span>
<span id="t23_163" class="t s4_163">chemotherapy. </span>
<span id="t24_163" class="t s5_163">308 </span>
<span id="t25_163" class="t s4_163">Results from a larger follow-up study suggest a survival </span>
<span id="t26_163" class="t s4_163">advantage. </span>
<span id="t27_163" class="t s5_163">309 </span>
<span id="t28_163" class="t s4_163">Other induction chemotherapy regimens have been evaluated in phase II </span>
<span id="t29_163" class="t s4_163">trials. The ECOG-ACRIN trial (E2303) showed promising results in terms </span>
<span id="t2a_163" class="t s4_163">of primary site response and survival for cetuximab, paclitaxel, and </span>
<span id="t2b_163" class="t s4_163">carboplatin as induction chemotherapy, followed by concurrent systemic </span>
<span id="t2c_163" class="t s4_163">therapy/RT with the same drug regimen in patients with stage III or IV </span>
<span id="t2d_163" class="t s4_163">SCCHN (</span><span id="t2e_163" class="t s6_163">N </span><span id="t2f_163" class="t s4_163">= 74), </span>
<span id="t2g_163" class="t s5_163">310 </span>
<span id="t2h_163" class="t s4_163">but the incremental benefit of induction chemotherapy </span>
<span id="t2i_163" class="t s4_163">requires validation using a randomized design. Two phase II studies </span>
<span id="t2j_163" class="t s4_163">evaluated the feasibility of TPF with cetuximab followed by concurrent </span>
<span id="t2k_163" class="t s4_163">systemic therapy/RT or RT alone. </span>
<span id="t2l_163" class="t s5_163">311,312 </span>
<span id="t2m_163" class="t s4_163">The DeLOS-II trial showed that </span>
<span id="t2n_163" class="t s4_163">TPF followed by RT, with cetuximab administered throughout, was </span>
<span id="t2o_163" class="t s4_163">feasible but not superior to TPF and subsequent RT without cetuximab. </span>
<span id="t2p_163" class="t s5_163">311 </span>
<span id="t2q_163" class="t s4_163">An EORTC trial evaluating this induction regimen followed by concurrent </span>
<span id="t2r_163" class="t s4_163">systemic therapy/RT was stopped prematurely due to numerous serious </span>
<span id="t2s_163" class="t s4_163">adverse events. </span>
<span id="t2t_163" class="t s5_163">312 </span>
<span id="t2u_163" class="t s4_163">There is a lack of consensus regarding the most appropriate concurrent </span>
<span id="t2v_163" class="t s4_163">systemic therapy/RT regimen to be administered following induction </span>
<span id="t2w_163" class="t s4_163">chemotherapy. </span>
<span id="t2x_163" class="t s5_163">313 </span>
<span id="t2y_163" class="t s4_163">Panel members agree that weekly carboplatin is a </span>
<span id="t2z_163" class="t s4_163">reasonable agent to use with RT. </span>
<span id="t30_163" class="t s5_163">306 </span>
<span id="t31_163" class="t s4_163">Intent-to-treat analyses from the </span>
<span id="t32_163" class="t s4_163">randomized phase II TREMPLIN study showed no significant difference in </span>
<span id="t33_163" class="t s7_163">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
